Ixabepilone: A new active chemotherapy in the treatment of breast cancer

Women's Health

Volumn 5, Issue 2, 2009, Pages 115-121

  Villanueva, Cristian ^a   Vuillemin, Antoine Thiery ^a   Demarchi, Martin ^a   Bazan, Fernando ^a   Chaigneau, Loïc ^a   Pivot, Xavier ^a,b  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b INSERM   (France)

Author keywords

Epothilone; Ixabepilone; Metastatic breast cancer; Phase III; Resistance to anthracyclines and taxanes

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FEC 100; IXABEPILONE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; EPOTHILONE DERIVATIVE; TUBULIN MODULATOR;

ANAPHYLAXIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RISK REDUCTION; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG RESISTANCE; FEMALE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUBULIN MODULATORS;

EID: 67650121136     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.5.2.115     Document Type: Article

References (33)

1. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24, 2137-2150 (2006).
2. Hortobagyi GN: Treatment of breast cancer. N. Engl. J. Med. 339, 974-984 (1998).
3. Valero V, Hortobagyi GN: Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J. Clin. Oncol. 21, 959-962 (2003).
4. Longley DB, Johnston PG: Molecular mechanisms of drug resistance. J. Pathol. 205, 275-292 (2005).
5. Pivot X, Asmar L, Buzdar AU et al.: An unified definition of clinical anthracycline resistance breast cancer. Br. J. Cancer 82(3), 529-534 (2000).
6. Talbot DC, Moiseyenko V, Van Belle S et al.: Randomised, Phase II trial comparing oral capecitabine (Xeloda®) with tumor in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br. J. Cancer 86, 1367-1372 (2002).
7. Pivot X, Dufresne A, Villanueva C: Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin. Breast Cancer 7, 543-549 (2007).
8. Hari M, Loganzo F, Annable T et al.: Tumor-resistant cells have a mutation in the tumor-binding region of β-tubulin (Asp26Glu) and less stable microtubules. Mol. Cancer Ther. 2, 270-278 (2006).
9. Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann. Oncol. 18(5), 3-8 (2007).
10. Fumoleau P, Coudert B, Isambert N et al.: Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann. Oncol. 18(5), 9-15 (2007).
11. Kolman A: Epothilone D (Kosan/Roche). Curr. Opin. Investig. Drugs 5, 657-667 (2004).
12. Aghajanian C, Burris HA 3rd, Jones S et al.: Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J. Clin. Oncol. 25(9), 1082-1088 (2007).
13. Mani S, McDaid H, Hamilton A et al.: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res. 10, 1289-1298 (2004).
14. Gadgeel SM, Wozniak A, Boinpally RR et al.: Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin. Cancer Res. 11(17), 6233-6239 (2005).
15. Abraham J, Agrawal M, Bakke S et al.: Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J. Clin. Oncol. 21, 1866-1873 (2003).
16. Roche H, Yelle L, Cognetti F et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol. 25, 3415-3420 (2007).
17. Denduluri N, Low JA, Lee JJ et al.: Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J. Clin. Oncol. 25(23), 3421-3427 (2007).
18. Thomas E, Tabernero J, Fornier M et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol. 25, 3399-3406 (2007).
19. Perez EA, Lerzo G, Pivot X et al.: Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 25, 3407-3414 (2007).
20. Low JA, Wedam SB, Lee JJ et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J. Clin. Oncol. 23, 2726-2734 (2005).
21. Lee JJ, Swain SM: Peripheral neuropathy induced by microtubule-stabilizing agents. J. Clin. Oncol. 24, 1633-1642 (2006).
22. Nabholtz JM, Gelmon K, Bontenbal M et al.: Multicenter, randomized comparative study of two doses of tumor in patients with metastatic breast cancer. J. Clin. Oncol. 14(6), 1858-1867 (1996).
23. Burstein HJ, Bellon JR, Galper S et al.: Prospective evaluation of concurrent tumor and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for stage II or III breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 64(2), 496-504 (2006).
24. Jones SE, Erban J, Overmoyer B et al.: Randomized Phase III study of docetaxel compared with tumor in metastatic breast cancer. Clin. Oncol. 23(24), 5542-5551 (2005).
25. Gradishar WJ, Tjulandin S, Davidson N et al.: Phase III trial of nanoparticle albumin-bound tumor compared with polyethylated castoroil-based tumor in women with breast cancer. J. Clin. Oncol. 23(31), 7794-7803 (2005).
26. Bunnell C, Vahdat L, Schwartzberg L et al.: Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin. Breast Cancer 8(3), 234-241 (2008).
27. Thomas ES, Gomez HL, Li RK et al.: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 25(33), 5210-5217 (2007).
28. Hortobagyi GN, Perez E, Vrdoljak E et al.: Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized Phase III trials. Program and Abstracts of the American Society of Clinical Oncology. Breast cancer symposium. Washington, DC, USA, 5-7 September (2008).
29. Thomas ES: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 26(13), 2223 (2008).
30. Rugo H, Thomas ES, Lee RK et al.: Combination therapy with ixabepilone plus capecitabine is effective in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. Breast Cancer Res. Treat. 106(1S), S270 (Abstract 6069) (2007).
31. Pivot XB, Lee RK, Thomas ES et al.: Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) resistant to anthracyclines/taxanes: subgroup analysis by estrogen receptor (ER) status. Program and Abstracts of the 2007 Breast Cancer Symposium. San Francisco, CA, USA, 7-8 September (2007).
32. Rugo H, Roche H, Thomas E et al.: Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled ana lysis of patients from two large Phase III clinical studies. Cancer Res. 69(Suppl. 2), 225S (Abstract 3057) (2009).
33. Baselga J, Zambetti M, Llombart-Cussac A et al.: Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J. Clin. Oncol. (2008).